284 related articles for article (PubMed ID: 24531702)
1. MRI and FDG-PET for assessment of response to neoadjuvant chemotherapy in locally advanced rectal cancer.
Aiba T; Uehara K; Nihashi T; Tsuzuki T; Yatsuya H; Yoshioka Y; Kato K; Nagino M
Ann Surg Oncol; 2014 Jun; 21(6):1801-8. PubMed ID: 24531702
[TBL] [Abstract][Full Text] [Related]
2. Standardized Index of Shape (DCE-MRI) and Standardized Uptake Value (PET/CT): Two quantitative approaches to discriminate chemo-radiotherapy locally advanced rectal cancer responders under a functional profile.
Petrillo A; Fusco R; Petrillo M; Granata V; Delrio P; Bianco F; Pecori B; Botti G; Tatangelo F; Caracò C; Aloj L; Avallone A; Lastoria S
Oncotarget; 2017 Jan; 8(5):8143-8153. PubMed ID: 28042958
[TBL] [Abstract][Full Text] [Related]
3. The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation.
Huh JW; Min JJ; Lee JH; Kim HR; Kim YJ
Am J Clin Oncol; 2012 Aug; 35(4):340-4. PubMed ID: 21422901
[TBL] [Abstract][Full Text] [Related]
4. Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?
Bampo C; Alessi A; Fantini S; Bertarelli G; de Braud F; Bombardieri E; Valvo F; Crippa F; Di Bartolomeo M; Mariani L; Milione M; Biondani P; Avuzzi B; Chiruzzi C; Pietrantonio F
Oncology; 2013; 84(4):191-9. PubMed ID: 23328390
[TBL] [Abstract][Full Text] [Related]
5. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
Luo J; Zhou Z; Yang Z; Chen X; Cheng J; Shao Z; Guo X; Tuan J; Fu X; Yu X
Medicine (Baltimore); 2016 Feb; 95(8):e2914. PubMed ID: 26937935
[TBL] [Abstract][Full Text] [Related]
6. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
[TBL] [Abstract][Full Text] [Related]
7. The value of pre- and post-neoadjuvant chemotherapy F-18 FDG PET/CT scans in breast cancer: comparison with MRI.
Choi EK; Yoo IR; Kim SH; Park SY; O JH; Kang BJ
Acta Radiol; 2018 Jan; 59(1):41-49. PubMed ID: 28427271
[TBL] [Abstract][Full Text] [Related]
8. Prediction of neoadjuvant radiation chemotherapy response and survival using pretreatment [(18)F]FDG PET/CT scans in locally advanced rectal cancer.
Bang JI; Ha S; Kang SB; Lee KW; Lee HS; Kim JS; Oh HK; Lee HY; Kim SE
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):422-31. PubMed ID: 26338180
[TBL] [Abstract][Full Text] [Related]
9. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
[TBL] [Abstract][Full Text] [Related]
10. (18)F-Fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) for the early detection of response to neoadjuvant chemotherapy for locally advanced rectal cancer.
Nishimura J; Hasegawa J; Ogawa Y; Miwa H; Uemura M; Haraguchi N; Hata T; Yamamoto H; Takemasa I; Mizushima T; Nezu R; Doki Y; Mori M
Surg Today; 2016 Oct; 46(10):1152-8. PubMed ID: 26711129
[TBL] [Abstract][Full Text] [Related]
11. Neither FDG-PET Nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study.
Guillem JG; Ruby JA; Leibold T; Akhurst TJ; Yeung HW; Gollub MJ; Ginsberg MS; Shia J; Suriawinata AA; Riedel ER; Mazumdar M; Saltz LB; Minsky BD; Nash GM; Paty PB; Temple LK; Weiser MR; Larson SM
Ann Surg; 2013 Aug; 258(2):289-95. PubMed ID: 23187748
[TBL] [Abstract][Full Text] [Related]
12. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
Koolen BB; Valdés Olmos RA; Wesseling J; Vogel WV; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Vrancken Peeters MJ
Ann Surg Oncol; 2013 Jul; 20(7):2227-35. PubMed ID: 23456316
[TBL] [Abstract][Full Text] [Related]
13. Utility of MRI and PET/CT after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity.
Kim T; Kang DK; An YS; Yim H; Jung YS; Kim KS; Kang SY; Kim TH
Acta Radiol; 2014 May; 55(4):399-408. PubMed ID: 23963151
[TBL] [Abstract][Full Text] [Related]
14. Interim Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Pathologic Response to Preoperative Chemoradiotherapy and Prognosis in Patients With Locally Advanced Rectal Cancer.
Koo PJ; Kim SJ; Chang S; Kwak JJ
Clin Colorectal Cancer; 2016 Dec; 15(4):e213-e219. PubMed ID: 27316919
[TBL] [Abstract][Full Text] [Related]
15. FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results.
Buchbender C; Kuemmel S; Hoffmann O; Stahl AR; Kimmig R; Otterbach F; Ladd S; Koeninger A; Forsting M; Bockisch A; Antoch G; Heusner TA
Acta Radiol; 2012 Jul; 53(6):628-36. PubMed ID: 22761341
[TBL] [Abstract][Full Text] [Related]
16. The role of dual-time combined 18-fluorodeoxyglucose positron emission tomography and computed tomography in the staging and restaging workup of locally advanced rectal cancer, treated with preoperative chemoradiation therapy and radical surgery.
Capirci C; Rubello D; Pasini F; Galeotti F; Bianchini E; Del Favero G; Panzavolta R; Crepaldi G; Rampin L; Facci E; Gava M; Banti E; Marano G
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1461-9. PubMed ID: 19419820
[TBL] [Abstract][Full Text] [Related]
17. Diffusion-weighted MRI and MR- volumetry--in the evaluation of tumor response after preoperative chemoradiotherapy in patients with locally advanced rectal cancer.
Birlik B; Obuz F; Elibol FD; Celik AO; Sokmen S; Terzi C; Sagol O; Sarioglu S; Gorken I; Oztop I
Magn Reson Imaging; 2015 Feb; 33(2):201-12. PubMed ID: 25460330
[TBL] [Abstract][Full Text] [Related]
18. Biological image-guided radiotherapy in rectal cancer: challenges and pitfalls.
Roels S; Slagmolen P; Nuyts J; Lee JA; Loeckx D; Maes F; Vandecaveye V; Stroobants S; Ectors N; Penninckx F; Haustermans K
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):782-90. PubMed ID: 19289265
[TBL] [Abstract][Full Text] [Related]
19. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
[TBL] [Abstract][Full Text] [Related]
20. Comparison of (18)F-FDG PET/CT methods of analysis for predicting response to neoadjuvant chemoradiation therapy in patients with locally advanced low rectal cancer.
Altini C; Niccoli Asabella A; De Luca R; Fanelli M; Caliandro C; Quartuccio N; Rubini D; Cistaro A; Montemurro S; Rubini G
Abdom Imaging; 2015 Jun; 40(5):1190-202. PubMed ID: 25348731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
